51 results
CORRESP
KPRX
Kiora Pharmaceuticals Inc
1 Dec 14
Correspondence with SEC
12:00am
in Amendment No. 6 to eliminate these inconsistencies.
Contractual Obligations, page 63
The total amount for the royalty license commitment does
CORRESP
KPRX
Kiora Pharmaceuticals Inc
12 Sep 14
Correspondence with SEC
12:00am
conversion feature that is in the money at the commitment date. The convertible debt contains a conversion feature in the event the Company raises
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities … upon, any other person or be used or relied upon for any other purpose. Wainwright shall not have the authority to make any commitment binding
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
. The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering … to make any commitment binding on the Company. The Company, in its sole discretion, shall have the right to reject any investor introduced
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
.
“This partnership confirms our commitment to advancing innovation in the treatment of unmet need for ophthalmic diseases,” said Jean-Frédéric Chibret
8-K
EX-10.1
0r5x7x01irjfv
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am
8-K
usdnu4m2f6tu8afxvh0d
26 Jul 22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
4:31pm
8-K
1z1336mnl4g2
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-10.1
b73yw59bfrmpm5lgb
26 Apr 22
Departure of Directors or Certain Officers
6:51am
8-K
EX-10.2
i879pipqbyw9adnp
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
PRE 14A
hv0 jg0ol6u
17 May 18
Preliminary proxy
5:21pm